Sugi Predict

Sugi Predict / Compounds / SCHEMBL4868635

SCHEMBL4868635

SCHEMBL4868635

CCc1ccc(CS(N)(=O)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 6/20 0.61
▸ CA1 P00915 2/20 0.60
▸ CA5A P35218 2/20 0.60
▸ CA9 Q16790 2/20 0.60
▸ KIF11 P52732 1/20 0.50
▸ TAAR1 Q96RJ0 1/20 0.44
▸ HPGD P15428 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ UCHL1 P09936 1/20 0.40
▸ GAA P10253 1/20 0.39
▸ PSIP1 O75475 1/20 0.39
▸ PLAU P00749 1/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ CYP2A6 P11509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11062961 0.81 CA2 (0.48) CA2CA1CA5ACA9KIF11
SCHEMBL3229364 0.81 CA1 (0.60) CA2CA1CA5ACA9KIF11
SCHEMBL4057569 0.79 CA1 (0.58) CA2CA1CA5ACA9KIF11
SCHEMBL4886230 0.79 CA2 (0.57) CA2CA1CA5ACA9KIF11
SCHEMBL4503685 0.78 CA2 (0.52) CA2TAAR1HPGDALDH1A1EGFR
SCHEMBL2984207 0.78 CA1 (0.62) CA2CA1CA5ACA9KIF11
SCHEMBL12309803 0.78 CA2 (0.52) CA2TAAR1HPGDALDH1A1EGFR
SCHEMBL4573294 0.78 CA2 (0.62) CA2CA1CA5ACA9KIF11
SCHEMBL17803562 0.77 KIF11 (0.56) CA2CA1CA5ACA9KIF11
SCHEMBL27804762 0.77 CA1 (0.61) CA2CA1CA5ACA9KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119255906-A Fireproof multilayer tubular structure for cooling electric vehicle batteries or stationary energy storage system batteries 阿科玛法国公司 2025-01-03 — — CN disclosed
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2023-05-25 — — US disclosed
CN-108863959-B P2X4 receptor antagonists 日本化学药品株式会社 2021-11-30 — — CN disclosed
CN-111333588-A P2X4 receptor antagonists 日本化学药品株式会社 2020-06-26 — — CN disclosed
EP-3227262-B1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS INC (US) 2020-05-13 — — EP disclosed
CN-104066724-B P2X4 receptor antagonists 日本化学药品株式会社 2020-04-17 — — CN disclosed
US-10428041-B2 Pyridyl reverse sulfonamides for HBV treatment NOVIRA THERAPEUTICS, INC. (US) 2019-10-01 — — US disclosed
US-20190152940-A1 Pyridyl Reverse Sulfonamides For HBV Treatment NOVIRA THERAPEUTICS, INC. 2019-05-23 — — US disclosed
US-10160742-B2 Pyridyl reverse sulfonamides for HBV treatment NOVIRA THERAPEUTICS, INC. (US) 2018-12-25 — — US disclosed
US-10119037-B2 Cellulose acetate wood filler compositions ACETATE INTERNATIONAL LLP (US) 2018-11-06 — — US disclosed
WO-2017100156-A2 CELLULOSE ACETATE WOOD FILLER COMPOSITIONS CELANESE INTERNATIONAL CORPORATION (US) 2017-06-15 — — WO disclosed
US-20170158881-A1 CELLULOSE ACETATE WOOD FILLER COMPOSITIONS ACETATE INTERNATIONAL LLC 2017-06-08 — — US disclosed
US-20160185748-A1 PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT NOVIRA THERAPEUTICS, INC. 2016-06-30 — — US disclosed
WO-2016089990-A1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS, INC. (US) 2016-06-09 — — WO disclosed
US-8299021-B2 Macrocyclic inhibitors of hepatitis C virus replication INTERMUNE, INC. (US) 2012-10-30 — — US disclosed
US-20120208995-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION ARRAY BIOPHARMA, INC. (US) 2012-08-16 — — US disclosed
US-20080312208-A1 Pyridine Analogues ASTRAZENECA AB (SE) 2008-12-18 — — US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 — — EP disclosed
US-20080039437-A1 New Pyridine Analogues III ASTRAZENECA AB (SE) 2008-02-14 — — US disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152940-A1 Pyridyl Reverse Sulfonamides For HBV Treatment HAVCR2, HCCS, NR1H4 CA2 3736/4885CA1 4332/4885CA5A 2279/4885
US-10428041-B2 Pyridyl reverse sulfonamides for HBV treatment HAVCR2, HCCS, NR1H4 CA2 3736/4885CA1 4332/4885CA5A 2279/4885
US-20080039437-A1 New Pyridine Analogues III P2RY12, P2RY1, P2RY11 CA2 3764/4885CA1 4845/4885CA5A 2613/4885
US-10160742-B2 Pyridyl reverse sulfonamides for HBV treatment HAVCR2, HCCS, NR1H4 CA2 3736/4885CA1 4332/4885CA5A 2279/4885
US-20120208995-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS CA2 4474/4885CA1 4665/4885CA5A 3867/4885
US-20080312208-A1 Pyridine Analogues P2RY12, P2RY11, P2RY1 CA2 3694/4885CA1 4880/4885CA5A 3175/4885
US-20160185748-A1 PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT HAVCR2, HCCS, NR1H4 CA2 3736/4885CA1 4332/4885CA5A 2279/4885
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF ENPP1, ENPP3, PPA1 CA2 1041/4885CA1 2081/4885CA5A 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.